106 related articles for article (PubMed ID: 215719)
1. Potentiation of coxsackievirus B3 infection in adult mice pretreated with a gold salt.
Kabiri M; Basiri E; Kadivar D
J Med Virol; 1978; 3(2):125-36. PubMed ID: 215719
[TBL] [Abstract][Full Text] [Related]
2. Role of antiviral antibodies in resistance against coxsackievirus B3 infection: interaction between preexisting antibodies and an interferon inducer.
Cho CT; Feng KK; McCarthy VP; Lenahan MF
Infect Immun; 1982 Aug; 37(2):720-7. PubMed ID: 6288570
[TBL] [Abstract][Full Text] [Related]
3. Coxsackievirus B3 persistence and myocarditis in NFR nu/nu and +/nu mice.
Schnurr DP; Schmidt NJ
Med Microbiol Immunol; 1984; 173(1):1-7. PubMed ID: 6088960
[TBL] [Abstract][Full Text] [Related]
4. Coxsackievirus infection of mice. II. Viral kinetics and histopathological changes in mice experimentally infected with coxsackievirus B3 by intraperitoneal route.
Vargová A; Bopegamage S; Borsanyiová M; Petrovicová A; Benkovicová M
Acta Virol; 2003; 47(4):253-7. PubMed ID: 15068381
[TBL] [Abstract][Full Text] [Related]
5. [Persistent infection caused by the Coxsackie B3 virus in adult mice].
Goriunova AG; Savinov AP
Vopr Virusol; 1987; 32(2):213-6. PubMed ID: 3037797
[TBL] [Abstract][Full Text] [Related]
6. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.
Slifka MK; Pagarigan R; Mena I; Feuer R; Whitton JL
J Virol; 2001 Mar; 75(5):2377-87. PubMed ID: 11160741
[TBL] [Abstract][Full Text] [Related]
7. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.
Yanagawa B; Spiller OB; Proctor DG; Choy J; Luo H; Zhang HM; Suarez A; Yang D; McManus BM
J Infect Dis; 2004 Apr; 189(8):1431-9. PubMed ID: 15073680
[TBL] [Abstract][Full Text] [Related]
8. Induction of heterotypic virus resistance in adult inbred mice immunized with a variant of Coxsackievirus B3.
Landau BJ; Whittier PS; Finkelstein SD; Alstein B; Grun JB; Schultz M; Crowell RL
Microb Pathog; 1990 Apr; 8(4):289-98. PubMed ID: 2166894
[TBL] [Abstract][Full Text] [Related]
9. Immunomodification and the expression of virulence in mice by defined strains of Semliki Forest virus: the effects of myocrisin and 1-asparaginase.
Bradish CJ; Allner K; Fitzgeorge R
J Gen Virol; 1975 Aug; 28(2):239-50. PubMed ID: 809543
[TBL] [Abstract][Full Text] [Related]
10. Murine natural killer cells limit coxsackievirus B3 replication.
Godeny EK; Gauntt CJ
J Immunol; 1987 Aug; 139(3):913-8. PubMed ID: 3036947
[TBL] [Abstract][Full Text] [Related]
11. The effects of pre-existing coxsackievirus B4 myocardial disease on the expression of coxsackievirus B3 myocarditis.
Khatib R; Reyes MP; Khatib G; Giraldo A
Can J Cardiol; 1993 Jun; 9(5):444-7. PubMed ID: 8394194
[TBL] [Abstract][Full Text] [Related]
12. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice.
Schmidtke M; Merkle I; Klingel K; Hammerschmidt E; Zautner AE; Wutzler P
J Med Virol; 2007 Sep; 79(9):1334-42. PubMed ID: 17607777
[TBL] [Abstract][Full Text] [Related]
13. Coxsackievirus B 1-induced polymyositis. Lack of disease expression in nu/nu mice.
Ytterberg SR; Mahowald ML; Messner RP
J Clin Invest; 1987 Aug; 80(2):499-506. PubMed ID: 3038960
[TBL] [Abstract][Full Text] [Related]
14. Coxsackievirus B3 replication and persistence in intestinal cells from mice infected orally and in the human CaCo-2 cell line.
Harrath R; Bourlet T; Delézay O; Douche-Aourik F; Omar S; Aouni M; Pozzetto B
J Med Virol; 2004 Oct; 74(2):283-90. PubMed ID: 15332278
[TBL] [Abstract][Full Text] [Related]
15. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
J Pharmacol Exp Ther; 1992 Mar; 260(3):1386-91. PubMed ID: 1372051
[TBL] [Abstract][Full Text] [Related]
16. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.
Henke A; Zell R; Ehrlich G; Stelzner A
J Virol; 2001 Sep; 75(17):8187-94. PubMed ID: 11483764
[TBL] [Abstract][Full Text] [Related]
17. Lack of correlation between neutralizing antibody production and suppression of coxsackievirus B-3 replication in target organs: evidence for involvement of mononuclear inflammatory cells in host defense.
Woodruff JF
J Immunol; 1979 Jul; 123(1):31-6. PubMed ID: 448152
[TBL] [Abstract][Full Text] [Related]
18. Coxsackievirus B3-induced chronic myocarditis in outbred NMRI mice.
Merkle I; Tonew M; Glück B; Schmidtke M; Egerer R; Stelzner A
J Hum Virol; 1999; 2(6):369-79. PubMed ID: 10774554
[TBL] [Abstract][Full Text] [Related]
19. Coxsackievirus infection of mice. I. Viral kinetics and histopathological changes in mice experimentally infected with coxsackieviruses B3 and B4 by oral route.
Bopegamage S; Borsanyiová M; Vargová A; Petrovicová A; Benkovicová M; Gomolcák P
Acta Virol; 2003; 47(4):245-51. PubMed ID: 15068380
[TBL] [Abstract][Full Text] [Related]
20. T cells expressing the Vgamma1 T-cell receptor enhance virus-neutralizing antibody response during coxsackievirus B3 infection of BALB/c mice: differences in male and female mice.
Huber S; Sartini D
Viral Immunol; 2005; 18(4):730-9. PubMed ID: 16359239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
